CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Market share analysis, 2016
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of rare diseases and various life-threatening conditions
3.4.1.2. Increase in demand for albumin
3.4.1.3. Growing preferences for recombinant albumin
3.4.1.4. Rise in non-therapeutic application of albumin

3.4.2. Restraints

3.4.2.1. Stringent government regulations
3.4.2.2. Risks associated with albumin

3.4.3. Opportunities

3.4.3.1. Opportunities in emerging economies
3.4.3.2. Development of cost effective therapeutics through large scale production

3.4.4. Impact analyses

3.5. Government regulations
3.6. Patent analysis (2013-2018)

3.6.1. Patent analysis, by year
3.6.2. Patent analysis for year 2017, by country

CHAPTER 4: ALBUMIN MARKET, BY PRODUCT

4.1. Overview

4.1.1. Market size and forecast

4.2. Human serum albumin

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Bovine serum albumin

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Recombinant albumin

4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

CHAPTER 5: ALBUMIN MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast (value)

5.2. Therapeutics

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Drug formulation & vaccines

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Component of media

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

5.5. Other applications

5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country

CHAPTER 6: ALBUMIN MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America albumin market, by country

6.2.2.1. U.S.

6.2.2.1.1. Market size and forecast, by product
6.2.2.1.2. Market size and forecast, by application

6.2.2.2. Canada

6.2.2.2.1. Market size and forecast, by product
6.2.2.2.2. Market size and forecast, by application

6.2.2.3. Mexico

6.2.2.3.1. Market size and forecast, by product
6.2.2.3.2. Market size and forecast, by application

6.2.3. North America market size and forecast, by product
6.2.4. North America market size and forecast, by application

6.3. Europe

6.3.1. Key market trends, growth factors and opportunities
6.3.2. Europe market size and forecast, by country

6.3.2.1. Germany

6.3.2.1.1. Market size and forecast, by product
6.3.2.1.2. Market size and forecast, by application

6.3.2.2. France

6.3.2.2.1. Market size and forecast, by product
6.3.2.2.2. Market size and forecast, by application

6.3.2.3. UK

6.3.2.3.1. Market size and forecast, by product
6.3.2.3.2. Market size and forecast, by application

6.3.2.4. Italy

6.3.2.4.1. Market size and forecast, by product
6.3.2.4.2. Market size and forecast, by application

6.3.2.5. Spain

6.3.2.5.1. Market size and forecast, by product
6.3.2.5.2. Market size and forecast, by application

6.3.2.6. Rest of Europe

6.3.2.6.1. Market size and forecast, by product
6.3.2.6.2. Market size and forecast, by application
6.3.2.6.3. Europe market size and forecast, by product
6.3.2.6.4. Europe market size and forecast, by application

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors and opportunities
6.4.2. Asia-Pacific market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Market size and forecast, by product
6.4.2.1.2. Market size and forecast, by application

6.4.2.2. China

6.4.2.2.1. Market size and forecast, by product
6.4.2.2.2. Market size and forecast, by application

6.4.2.3. India

6.4.2.3.1. Market size and forecast, by product
6.4.2.3.2. Market size and forecast, by application

6.4.2.4. Australia

6.4.2.4.1. Market size and forecast, by product
6.4.2.4.2. Market size and forecast, by application

6.4.2.5. South Korea

6.4.2.5.1. Market size and forecast, by product
6.4.2.5.2. Market size and forecast, by application

6.4.2.6. Rest of Asia-Pacific

6.4.2.6.1. Market size and forecast, by product
6.4.2.6.2. Market size and forecast, by application

6.4.3. Asia-Pacific market size and forecast, by product
6.4.4. Asia-Pacific market size and forecast, by application

6.5. LAMEA

6.5.1. Key market trends, growth factors and opportunities
6.5.2. LAMEA market size and forecast, by country

6.5.2.1. Brazil

6.5.2.1.1. Market size and forecast, by product
6.5.2.1.2. Market size and forecast, by application

6.5.2.2. Saudi Arabia

6.5.2.2.1. Market size and forecast, by product
6.5.2.2.2. Market size and forecast, by application

6.5.2.3. South Africa

6.5.2.3.1. Market size and forecast, by type
6.5.2.3.2. Market size and forecast, by application

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Market size and forecast, by product
6.5.2.4.2. Market size and forecast, by application

6.5.3. LAMEA market size and forecast, by product
6.5.4. LAMEA market size and forecast, by application

CHAPTER 7: COMPANY PROFILES

7.1. Baxter International Inc.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance

7.2. China Biologic Products Holdings, Inc.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance

7.3. CSL Limited

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance

7.4. Grifols S.A. (Grifols International, S.A.)

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. Merck KGaA

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. Novozymes A/S (Albumedix Ltd.)

7.6.1. Company overview
7.6.2. Operating business segments
7.6.3. Product portfolio
7.6.4. Business performance

7.7. Octapharma AG

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance

7.8. Shire Plc. (Shire US, Inc.)

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. Thermo Fisher Scientific Inc (Affymetrix, Inc.)

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. Ventria Bioscience

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating product categories
7.10.4. Product portfolio